Worldwide Biologics and Biosimilars market is valued at 144.7 Billion US$ in 2017 and will reach 220.3 Billion US$ by the end of 2025, growing at a CAGR of 5.4% during 2018-2025.

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include […]

Read More

Worldwide Biologics and Biosimilars market is valued at 144.7 Billion US$ in 2017 and will reach 220.3 Billion US$ by the end of 2025, growing at a CAGR of 5.4% during 2018-2025.

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include […]

Read More